Alternatives to carbapenems in ESBL-producing Escherichia coli infections

Medecine et Maladies Infectieuses

Volumn 43, Issue 2, 2013, Pages 62-66

  Fournier, D ^a   Chirouze, C ^a   Leroy, J ^a   Cholley, P ^a,b   Talon, D ^a,b   Plesiat P ^a   Bertrand, X ^a,b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Antibiotic resistance; ESBL; Escherichia coli

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; FOSFOMYCIN; MECILLINAM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; PIVMECILLINAM; TEMOCILLIN; TIGECYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; IN VITRO STUDY; IN VIVO STUDY; INFECTION RESISTANCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; HUMANS; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 84875810460     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2013.01.006     Document Type: Article

References (29)

1. Canton R., Novais A., Valverde A., Machado E., Peixe L., Baquero F., et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008, 14(Suppl 1):144-153.
2. Valverde A., Coque T.M., Sanchez-Moreno M.P., Rollan A., Baquero F., Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004, 42:4769-4775.
3. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004, 48:1-14.
4. Pitout J.D. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010, 70:313-333.
5. Nordmann P., Naas T., Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011, 17:1791-1798.
6. European Committee on Antimicrobial Susceptibility Testing (EUCAST 2012). Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0. Available at http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_2.0_120221.pdf.
7. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial. susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition, 2009.
8. Garrec H., Drieux-Rouzet L., Golmard J.L., Jarlier V., Robert J. Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by Enterobacteriaceae. J Clin Microbiol 2011, 49:1048-1057.
9. Tarnberg M., Ostholm-Balkhed A., Monstein H.J., Hallgren A., Hanberger H., Nilsson L.E. In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2011, 30:981-987.
10. Brasme L., Nordmann P., Fidel F., Lartigue M.F., Bajolet O., Poirel L., et al. Incidence of class A extended-spectrum beta-lactamases in Champagne-Ardenne (France): a 1year prospective study. J Antimicrob Chemother 2007, 60:956-964.
11. Peirano G., Pitout J.D. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2010, 35:316-321.
12. Rodriguez-Bano J., Alcala J.C., Cisneros J.M., Grill F., Oliver A., Horcajada J.P., et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008, 168:1897-1902.
13. de Cueto M., Hernandez J.R., Lopez-Cerero L., Morillo C., Pascual A. Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. Enferm Infect Microbiol Clin 2006, 24:613-616.
14. Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008, 14(Suppl 1):198-202.
15. Pitout J.D., Gregson D.B., Campbell L., Laupland K.B. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother 2009, 53:2846-2851.
16. Puerto A.S., Fernandez J.G., del Castillo Jde D., Pino M.J., Angulo G.P. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli. Diagn Microbiol Infect Dis 2006, 54:135-139.
17. Kelesidis T., Karageorgopoulos D.E., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008, 62:895-904.
18. Falagas M.E., Karageorgopoulos D.E., Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab 2009, 10:13-21.
19. Geerlings S.E., van Donselaar-van der Pant K.A., Keur I. Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 2010, 65:2048-2049.
20. Kerrn M.B., Frimodt-Moller N., Espersen F. Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole. Clin Microbiol Infect 2004, 10:54-61.
21. Livermore D.M., Hope R., Fagan E.J., Warner M., Woodford N., Potz N. Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 2006, 57:1012-1014.
22. Balakrishnan I., Awad-El-Kariem F.M., Aali A., Kumari P., Mulla R., Tan B., et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2011, 66:2628-2631.
23. Oteo J., Navarro C., Cercenado E., Delgado-Iribarren A., Wilhelmi I., Orden B., et al. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol 2006, 44:2359-2366.
24. Prakash V., Lewis J.S., Herrera M.L., Wickes B.L., Jorgensen J.H. Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2009, 53:1278-1280.
25. Rodriguez-Villalobos H., Malaviolle V., Frankard J., de Mendonca R., Nonhoff C., Struelens M.J. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 2006, 57:771-774.
26. Gavin P.J., Suseno M.T., Thomson R.B., Gaydos J.M., Pierson C.L., Halstead D.C., et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 2006, 50:2244-2247.
27. Rodriguez-Bano J., Navarro M.D., Retamar P., Picon E., Pascual A. Beta-lactam/beta-lactam inhibitor combinations for the treatment of cacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012, 54:167-174.
28. Lee C.H., Su L.H., Tang Y.F., Liu J.W. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 2006, 58:1074-1077.
29. Bin C., Hui W., Renyuan Z., Yongzhong N., Xiuli X., Yingchun X., et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 2006, 56:351-357.